Phenibut (Discussion).
Russian anxiety drug. High addiction potential. A lab-built version of GABA carrying an extra ring so it crosses into the brain. It acts at GABA-B receptors, which is what people take it for: a few hours of loosened calm.
Reviewed March 2026
What Phenibut (Discussion) is, and what it does.
- Does it work
- Suits adults who want an occasional calm evening and will leave days between doses. Tolerance builds quickly on repeated dosing, so short spaced use is how this one is handled.
- How much to take
- The band on record is 250mg to 500mg a day, with 1,000mg appearing only as a research condition. Spacing days apart matters more here than the number on the scoop.
- Time to feel it
- Onset is slow, roughly two to four hours, and it shifts with what you ate. That delay is the single most common reason people take a second dose too early.
- The first dose
- Several hours of loosened, sedated calm, then a duller stretch as GABA-B signalling rebounds. Alcohol on the same day compounds the sedation considerably.
- With regular use
- Most effects take 2-8 weeks. Be patient.
- How well tolerated
- Generally well tolerated. Check with your doctor if on medications.
- How it feels
- Powerful anxiety relief. HIGHLY addictive. Use rarely.
- The overlooked benefit
- It leaves largely unchanged through the kidneys rather than being broken down by liver enzymes, so kidney function, not liver traffic, sets how long it hangs around.
250 to 500mg a day is where Phenibut (Discussion) works.
Source: Lapin, 2001, CNS Drug Rev
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Based on 10 human trials.
- calm and social easeNarrative review
- sedation and reduced neuronal excitabilityAnimal study
- tolerance and rebound excitability after sustained dosingNarrative review
- GABA-B receptor agonism and alpha2delta calcium channel bindingIn vitro study
Questions people ask about Phenibut (Discussion).
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- Honestly, most people would benefit more from the basics. But if you've got a specific reason to try it, the risk is generally low.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Phenibut acts as a GABA-B agonist and ethanol acts broadly across GABA-A and glutamate systems, so the two add together on the same downward direction of central nervous system arousal. This is a settled additive interaction and the pairing should be avoided.
Phenibut is a phenyl-substituted GABA analogue built specifically to cross into the central nervous system, and it acts at GABA-B sites. Adding supplemental GABA layers input onto the same inhibitory family.
Picamilon is GABA joined to niacin as a carrier that releases GABA centrally, so it delivers into the same inhibitory system phenibut acts on. The two are structurally and mechanistically overlapping rather than complementary.
Kavalactones modulate GABA-A receptors and voltage-gated sodium channels, which adds to phenibut's GABA-B action on the same overall arousal state. The combination compounds sedation.
Valerenic acid modulates the GABA-A receptor, so it pushes arousal in the same direction as a GABA-B agonist. Stacking the two deepens sedation beyond either alone.
Honokiol and magnolol are positive modulators at the GABA-A receptor. Combined with a GABA-B agonist the two act on the same inhibitory outcome from different receptor subtypes.
Melatonin lowers arousal through MT1 and MT2 receptors on a different pathway from GABA-B, but the two effects on wakefulness add. Anyone combining them should expect more drowsiness than either alone.
Phenibut is a GABA-B receptor agonist, while theanine is a glutamate analogue that modulates glutamatergic and alpha-wave activity rather than binding GABA-B. Combining them stacks two routes toward reduced neuronal excitability, so calming effects may add rather than simply overlap. The pair has not been measured together, so the size of any combined effect is not known.
Magnesium blocks the NMDA receptor channel pore in a voltage-dependent way, damping excitatory glutamate signalling from the opposite side of the excitation balance that phenibut works on. The two act on different receptor families, so the calming effect is additive rather than redundant. Direction is predictable from mechanism; the size of any combined effect in people has not been measured.
Glycine is itself an inhibitory neurotransmitter at strychnine-sensitive glycine receptors, mostly in the spinal cord and brainstem, and also acts as a co-agonist at NMDA receptors. Phenibut works through GABA-B receptors and calcium channel alpha2delta subunits, a separate set of targets. Two inhibitory inputs in one dose can compound the sedative direction.
Pyridoxal-5-phosphate is the obligate cofactor for glutamate decarboxylase, the enzyme that converts glutamate into GABA, and also for GABA transaminase, which degrades it. Endogenous GABA tone therefore depends on adequate B6 status regardless of what a GABA-B agonist is doing at the receptor. This is a substrate-supply relationship, not evidence that B6 changes the response to phenibut.
Passionflower preparations are used for their calming effect and their flavonoid constituents have been described as modulating GABA-A signalling in laboratory work. Stacking a botanical calmative with a GABA-B agonist compounds sedation. The combination itself has not been characterised in a controlled setting.
Chamomile carries apigenin, a flavone that binds the benzodiazepine site on GABA-A receptors in binding assays. That is a different receptor family from the GABA-B target of phenibut, so the two calming effects can add. Read this as mechanistic rather than clinical.
Lemon balm constituents including rosmarinic acid have been reported to inhibit GABA transaminase in vitro, which would slow GABA breakdown. Paired with a direct GABA-B agonist, the calming direction compounds. The interaction is inferred from separate mechanisms rather than measured together.
Ashwagandha withanolides have shown GABA-mimetic activity in receptor work and the herb is used to support a normal stress response. Combined with a GABA-B agonist the sedative direction adds. The pair has not been studied as a combination.
Caffeine is an adenosine receptor antagonist and raises central arousal, the opposite direction to GABA-B agonism. Taken together, the two can mask each other, so the subjective read on either one becomes unreliable. That masking is the reason the pairing deserves flagging rather than recommending.
5-HTP is the immediate precursor to serotonin and shifts monoamine signalling, a separate axis from GABA-B agonism. Stacking a serotonergic precursor with a sedating agonist changes two systems at once and makes attribution of any effect difficult. Flagged for that reason rather than for a demonstrated benefit.
Tryptophan feeds serotonin and downstream melatonin synthesis, supporting normal sleep onset by a route independent of GABA-B receptors. Combined sedative direction is plausible on mechanism alone. No combination data exist.
Nothing specific on file for Phenibut (Discussion). Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Phenibut (Discussion) actually does.
It is GABA with a ring added on, and that ring is what lets it reach the brain when plain GABA largely cannot.
It switches on GABA-B receptors, which quiet down how readily nerve cells fire and release signals.
Keep pushing the same receptor and it turns itself down, so the effect fades with repeated use and stopping suddenly swings the other way.
At higher amounts it also sticks to a calcium channel subunit, the same spot gabapentinoids use.
Where Phenibut (Discussion) comes from.
It is made in a chemical plant from simple industrial starting materials. Nothing about it is extracted from a plant.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Two commodity petrochemical-derived reagents are condensed in a Henry reaction to give beta-nitrostyrene, the aromatic building block that becomes the phenyl-bearing carbon.
A malonate ester adds across the nitroalkene, installing the carbon skeleton of the four-carbon butanoic acid chain with the phenyl group on the beta carbon.
The nitro group is reduced to a primary amine, which cyclises onto the adjacent ester to give a lactam intermediate.
Acidic or basic hydrolysis of the lactam opens the ring and, with decarboxylation of the residual ester carbon, yields racemic 4-amino-3-phenylbutanoic acid.
The product is recrystallised, most often as the hydrochloride from an alcohol or water-alcohol system, which is also where residual solvent and nitro-intermediate carryover are controlled.
The material is isolated either as the hydrochloride or converted to the free amino acid, then milled to a defined particle size for capsule or powder filling.
Manufacturers rarely disclose which of the several published synthetic routes was used, or whether the material is racemic or resolved.
Getting Phenibut (Discussion) from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- The report documents the clinical course after a single accidental ingestion in one animal and the supportive care given.Case report. Sahagian et al., 2023 (Journal of Veterinary Emergency and Critical Care). PMID 37436877 ↗
These are the studies our verdict leans on, chosen from the 1 we read for Phenibut (Discussion). The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.